49
https://pubmed.ncbi.nlm.nih.gov/38116441
Researchers have developed conformationally restricted analogues of α-galactosylceramide that enhance the immune response to a COVID-19 subunit vaccine in mice, and omitting certain adjuvants in the booster vaccine has minimal impact on antibody and cellular responses.